AdAlta investor briefing – progress of AD-214 Phase I extension study

On 10 August 2023, AdAlta’s CEO and Managing Director, Dr Tim Oldham provided an update on lead drug AD-214, including the dosing of first participants in the Phase I extension study, recent data demonstrating potential efficacy of clinically convenient doses and partnering progress. The AD-214 Phase 1 extension study will generate valuable data to inform and de-risk the design of the future AD-214 Phase II study, and progress partnering discussions. During the webinar, Dr Oldham also discussed the unmet need for improved treatments for lung fibrosis patients for whom AD-214 is being developed. He highlighted Long Kayak for Lungs 2 , the latest initiative by IPF survivor Bill Van Nierop to raise awareness of and funds for research into IPF, which AdAlta is supporting. Click below to watch:

The release as fetched from its publisher. adalta.com.au ↗